Quarterly Cashflow and Activities Report (ASX Announcement)

Apr 29th, 2022

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2022.

Starpharma to present DEP® at Boston ADC summit (ASX Announcement)

Apr 27th, 2022

Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it will today present as an invited speaker at the Novel Format Conjugates Summit, an industry conference focusing on next generation Non-Traditional Antibody Drug Conjugates (ADCs) for oncology and beyond.

Dr Jeff Davies appointed as non-executive director (ASX Announcement)

Apr 1st, 2022

VIRALEZE™ to relaunch in the UK (ASX Announcement)

Apr 1st, 2022

Starpharma today announced that it has successfully resolved the queries raised last year by the UK Medicines and Healthcare products Regulatory Agency (MHRA), clearing the way for the relaunch of VIRALEZE™ in the UK as soon as possible.

Response to media article (ASX Announcement)

Mar 4th, 2022

Starpharma notes the media article published in The Age / Sydney Morning Herald this morning, titled ‘Nasal spray not on Australian shelves’, and provides the following information.

SPL7013 in VIRALEZE™ virucidal against Omicron (ASX Announcement)

Mar 1st, 2022

Starpharma today announced that SPL7013, the antiviral agent in VIRALEZE™ antiviral nasal spray, achieved the maximal possible reduction of virus infectivity (>95% within 1 minute of exposure and >99% within 5 minutes, achieving a maximal reduction of >99.5%) against the Omicron variant of SARS-CoV-2, in laboratory-based antiviral and virucidal assays. Testing of SPL7013 against Omicron was conducted in the laboratory of internationally recognised virologist, Professor Philippe Gallay, at The Scripps Research Institute in the US.

Dr Jeff Davies appointed as non-executive director (ASX Announcement)

Feb 24th, 2022

Starpharma Holdings Limited The Board of Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Jeff Davies as an independent non-executive director, effective 1 April 2022.  

Starpharma Interim Report and Half-Year Financial Results (ASX Announcement)

Feb 21st, 2022

Starpharma today released its interim report and financial results for the half-year ended 31 December 2021.

VIRALEZE™ sales and distribution in Saudi Arabia and GCC (ASX Announcement)

Feb 3rd, 2022

Starpharma today announced it has signed an exclusive sales and distribution agreement for VIRALEZE™ antiviral nasal spray in Saudi Arabia and eight other countries, including the GCC^[1] countries  (United Arab Emirates, Qatar, Kuwait, Oman, and Bahrain), with Etqan & Nazahah LLC (E&N). E&N is an agent and distributor of medical and pharmaceutical products, headquartered in Saudi Arabia, that represents international healthcare companies, including Bayer, in the GCC region and other neighbouring countries.

Quarterly Cashflow and Activities Report (ASX Announcement)

Jan 28th, 2022

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 December 2021.

Starpharma receives $7.7M R&D tax incentive refund (ASX Announcement)

Jan 20th, 2022

Starpharma today announced it has received a $7.7M research and development (R&D) tax incentive refund related to the company’s Australian and international R&D expenses from the 2021 financial year. The tax refund is for eligible R&D activities across Starpharma’s portfolio, including the company’s DEP^® oncology products and VIRALEZE™ antiviral nasal spray.

Shareholder Newsletter December 2021

Dec 16th, 2021

The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Update – December 2021 is now available to view online.

VIRALEZE™ antiviral nasal spray registered in Saudi Arabia (ASX Announcement)

Dec 14th, 2021

Starpharma today announced that VIRALEZE™ antiviral nasal spray has been registered for sale in Saudi Arabia. This is the first registration for VIRALEZE™ in the Middle East and registration in Saudi Arabia is an important step for other countries in the region.

VIRALEZE™ successfully launched in Vietnam (ASX Announcement)

Dec 13th, 2021

Starpharma today announced that since signing the commercial arrangement for VIRALEZE™ antiviral nasal spray in Vietnam, the company has received orders in excess of A$2 million, since late October. Some orders have already been delivered with further product expected to be delivered in the New Year. VIRALEZE™ successfully launched in Vietnam last week, with the formal launch events attended by clinicians, healthcare professionals, politicians, and media representatives from over 30 news channels.

VIRALEZE™ distribution agreement and launch in Vietnam (ASX Announcement)

Dec 3rd, 2021

Starpharma today announced it has signed an ongoing distribution arrangement for VIRALEZE™ antiviral nasal spray in Vietnam with Australian-based Healthco Australia Pty Ltd (HealthCo), with Vietnam-based Truong Bao Land (TBL), and Nam Thanh Trade and Medical Services Company Limited (NTM) responsible for importation and distribution locally in Vietnam. The distribution agreement includes a minimum commitment of at least 1 million units of VIRALEZE™ in the first year. The official product launch is scheduled to occur in Vietnam today following registration of VIRALEZE™ announced earlier this week.

VIRALEZE™ registered in Vietnam with launch this week (ASX Announcement)

Dec 1st, 2021

Starpharma today announced it has received confirmation that VIRALEZE™ antiviral nasal spray has been registered for sale in Vietnam. The product launch is scheduled to occur in Vietnam this week with product supplied under the initial supply distribution arrangements, with Australian-based Healthco Australia Pty Ltd (HealthCo), and Vietnam-based Truong Bao Land International Investment Company Limited (TBL). TBL will also utilise the local medical distribution networks in Vietnam, including Nam Thanh Trade and Medical Services Company Limited.

Novel Cabazitaxel Formulation Shows Promise for Metastatic Prostate Cancer

Nov 30th, 2021

Targeted Oncology features Starpharma's latest DEP® announcement - the release of positive interim results from the prostate cancer cohort of Starpharma's ongoing phase 2 trial of DEP® cabazitaxel.

AGM Chairman’s address and CEO’s presentation (ASX Announcement)

Nov 30th, 2021

Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbourne time) today.

Starpharma reports positive interim results from Phase 2 DEP cabazitaxel study in prostate cancer

Nov 27th, 2021

Starpharma's positive interim results from its ongoing phase 2 trial of DEP cabazitaxel featured in Seeking Alpha. 

Starpharma Releases Positive DEP® Phase 2 Interim Results In Prostate Cancer

Nov 27th, 2021

British Herald reports on Starpharma's announcement, regarding the positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP^® cabazitaxel.

Starpharma Announces Encouraging Interim Results for Prostate Cancer Drug

Nov 27th, 2021

Gene Online reports on the news of Starpharma's latest announcement - the release of positive interim results from the prostate cancer cohort of Starpharma's ongoing phase 2 trial of DEP® cabazitaxel. 

Positive DEP® phase 2 interim results in prostate cancer (ASX Announcement)

Nov 25th, 2021

Starpharma today announced positive interim results from its ongoing phase 2 trial of DEP^® cabazitaxel, showing that 100% (22/22) of evaluable patients with hormone refractory, (Stage IV) metastatic prostate cancer. All of these patients have been heavily pre-treated and have had efficacy responses, utilising one or more standard measures of disease.

Starpharma to present at Bell Potter Healthcare Conference (ASX Announcement)

Nov 9th, 2021

Starpharma has been invited to present today at the exclusive virtual 2021 Bell Potter Healthcare Conference. The Bell Potter Healthcare Conference showcases leading companies within the Australian healthcare sector and brings together industry leaders with Bell Potter’s network of international and domestic investors, analysts and advisers. The event is available to live-stream via Bell Potter Client Access on 9 – 11 November.

AstraZeneca to present AZD0466 posters at ASH Meeting

Nov 5th, 2021

AstraZeneca will present two scientific posters each accompanied by a presentation at the 2021 American Society of Hematology (ASH) Annual Meeting, showcasing AstraZeneca’s first DEP^® oncology product, AZD0466.

Quarterly Cashflow and Activities Report (ASX Announcement)

Oct 29th, 2021

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2021.

Starpharma to present DEP® at US Drug Delivery Conference (ASX Announcement)

Oct 28th, 2021

Starpharma today announced that it has been invited to present at the 11^th annual Partnership Opportunities in Drug Delivery (PODD) conference, which will take place virtually this year on 28‑29 October 2021.

VIRALEZE™ distribution and supply to Vietnam (ASX Announcement)

Oct 26th, 2021

Starpharma today announced it has signed an initial supply contract for VIRALEZE™ antiviral nasal spray in Vietnam and first delivery into Vietnam is expected in early November. In parallel with completing registration, Starpharma is finalising an ongoing distribution agreement for VIRALEZE™ in Vietnam which will allow subsequent larger orders and ongoing supply.

VIRALEZE™ launch in ADMENTA Italia Group pharmacies in Italy (ASX Announcement)

Oct 8th, 2021

Starpharma today announced it has signed a sales and distribution agreement for VIRALEZE™ antiviral nasal spray with ADMENTA Italia Group (ADMENTA), a leading pharmaceutical retail and wholesale distribution company in Italy. 

2021 Annual General Meeting (ASX Announcement)

Oct 1st, 2021

Starpharma today notifies that the AGM of Starpharma Holdings Limited will be held as a virtual event at 11:00am (Melbourne time) on Tuesday, 30 November 2021.

US patent issued for DEP® cabazitaxel nanoparticle (ASX Announcement)

Sep 15th, 2021

Starpharma today announced that the US Patent and Trademark Office has granted a new patent in relation to DEP^® cabazitaxel.

Starpharma annual report and full year financial results (ASX Announcement)

Aug 26th, 2021

Starpharma today released its annual report and financial results for the year ended 30 June 2021.

VIRALEZE™ Protects Against SARS-CoV-2 in Challenge Model (ASX Announcement)

Aug 23rd, 2021

Starpharma today announced publication of new data demonstrating the protective efficacy of VIRALEZE™ antiviral nasal spray against SARS-CoV-2 challenge in vivo in a humanised mouse model of coronavirus infection. The results of the study have been published in the international peer-reviewed journal, Viruses, in a special issue titled, Medical Interventions for Treatment and Prevention of SARS-CoV-2 Infections (https://www.mdpi.com/1999-4915/13/8/1656).

VIRALEZE™ well tolerated in multiple dose clinical study (ASX Announcement)

Aug 17th, 2021

Starpharma today announced results from its VIRALEZE™ clinical safety study demonstrating the product was safe and well tolerated in accordance with the primary endpoint, and also confirming that the dendrimer antiviral in VIRALEZE™, SPL7013, was not absorbed into the bloodstream following nasal application.  

Quarterly Cashflow and Activities Report (ASX Announcement)

Jul 30th, 2021

Starpharma (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2021.

Lynda Cheng appointed as non-executive director (ASX Announcement)

Jul 28th, 2021

Starpharma to present DEP® platform at CRS Annual Meeting (ASX Announcement)

Jul 27th, 2021

Starpharma (ASX:SPL) shows 99.99pc antiviral activity against Delta COVID-19 variant

Jul 27th, 2021

VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant (ASX Announcement)

Jul 27th, 2021

Starpharma today announced new data demonstrating that SPL7013, the antiviral agent in VIRALEZE™ nasal spray, is active against the highly transmissible Delta variant of SARS-CoV-2, achieving more than 99.99% reduction of infectious virus in laboratory-based virucidal assays.

TGA infringement notices for alleged advertising (ASX Announcement)

Jul 5th, 2021

Starpharma today announces it has received several infringement notices from the TGA with respect to alleged advertising of VIRALEZE™ antiviral nasal spray to Australian consumers.

Starpharma to present at Virtual Life Sciences Investor Forum (ASX Announcement)

Jun 24th, 2021

Starpharma today announced that a presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 24 June 2021 (US ET) as part of OTCQX’s Virtual Life Sciences Investor Forum. The Life Sciences Investor Forum is a leading investor conference that is attended by tens of thousands of investors, primarily US-based retail investors, as well as advisors.

VIRALEZE UK update (ASX Announcement)

Jun 21st, 2021

Starpharma advises that its UK retail partner, LloydsPharmacy, has received correspondence from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in relation to specific promotional claims made for VIRALEZE™ antiviral nasal spray.

VIRALEZE SPL7013 virucidal against multiple COVID variants (ASX Announcement)

Jun 18th, 2021

Starpharma today released new data demonstrating that SPL7013, the active in VIRALEZE^™ antiviral nasal spray, achieved more than 99.9% reduction of virus against the Alpha (UK), Beta (South Africa) and Gamma (Japan/Brazil) SARS-CoV-2 coronavirus ‘Variants of Concern’ in laboratory-based virucidal assays.

VIRALEZE antiviral nasal spray registered for sale in India (ASX Announcement)

Jun 11th, 2021

Starpharma today announced it had received confirmation that VIRALEZE^™ antiviral nasal spray has been registered for sale nationally in India via the Central Drugs Standard Control Organisation (CDSCO), which is part of the Indian Ministry of Health and Family Welfare.

VIRALEZE SPL7013 highly active in UK variant of coronavirus (ASX Announcement)

Jun 1st, 2021

Starpharma today announced new data confirming that SPL7013, the active in VIRALEZE^™ antiviral nasal spray, has potent antiviral activity against the UK (B.1.1.7) SARS-CoV-2 variant of concern (hCoV-19/England/204820464/2020) in laboratory studies, achieving more than 98% reduction in infectious virus in antiviral assays.

VIRALEZE™ partners with Harlequins in the UK (ASX Announcement)

May 11th, 2021

Starpharma attaches a media release announcing the partnership between VIRALEZE™ and Harlequins in the UK, which was distributed today. (Click here)

Harlequins is a professional English rugby union team, established in 1866, and one of the founding members of the Rugby Football Union. Harlequins play in the English Premiership, the top level of English rugby union. The Club’s home ground is the Twickenham Stoop Stadium, “The Stoop”, in south-west London. For more information about Harlequins, visit www.quins.co.uk.

VIRALEZE™ launches in Europe (ASX Announcement)

May 6th, 2021

Starpharma today announced that VIRALEZE^™ antiviral nasal spray is now available for purchase by consumers in Europe via Starpharma’s www.viraleze.co webstore.

Shareholder Update April 2021

Apr 28th, 2021

The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Update – April 2021 is now available to view online.

Quarterly Cashflow and Activities Report

Apr 27th, 2021

Starpharma (ASX: SPL, OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2021.

VIRALEZE™ now launched by LloydsPharmacy in the UK

Mar 30th, 2021

Starpharma today confirms that Starpharma’s VIRALEZE™ antiviral nasal spray has launched in the UK by LloydsPharmacy, as announced on 25 March 2021.

VIRALEZE™ to be launched with LloydsPharmacy in the UK

Mar 25th, 2021

Starpharma today announced it has signed a sales and distribution agreement for VIRALEZE™ antiviral nasal spray with LloydsPharmacy and the McKesson group in the UK. LloydsPharmacy/McKesson is one of the largest pharmacy groups in the UK and is also a major wholesaler in the UK.